Treatment of the B16F10 tumor-bearing mice with PL1-OX40 (ψ) + anti-OX40 Ab (40 μg) significantly decreased tumor growth and prolonged survival in comparison to PBS and PL1 + anti-OX40 treatment (Fig. 4a–d). The gene discussed is TNFRSF4; the disease is neoplasm.